In the 1950s, with the China government's policy of merging state-owned
pharmaceutical enterprises with the private sector, Tianjin Municipal Chinese
Medicinal Materials Corpn (TMCM) merged and reorganised the various factories
and stores in Tianjin. In December 1992, TMCM was converted from a state-owned
enterprise to a company limited by shares whereby shares were issued to legal
persons and its employees. In connection therewith, it was renamed Tianjin
Traditional Chinese Medicine Group Co Ltd (TTCM). Following the
corporatisation of the Company, the shares issued to the employees were traded
at the Tianjin Securities Trading Centre.
In conjunction with the proposed public offering, TTCM adopted its present
name. Pursuant to the restructuring, it became the holding company for the
Group.
The Group's businesses cover a wide range of products including Chinese patent
medicine, Chinese medicinal drinks, Chinese medicinal raw materials,
biotechnology medicine, chemical raw material medicine and preparations, and
nutritional and health products. It has over 800 medicinal products in over 20
types of formulations. The main products are Suxiao Jiuxin pill (used for
treatment of heart disease), Huoxiang Zhengqi Soft capsule (used for treatment
of intestines and stomach disease), Gengnian An (used for treatment of
menopause symptoms), Zi Long Jin tablet (used for treatment of cancer), Xuefu
Zhuyu capsule (used for treatment of diseases relating to heart and head blood
vessel), Biqi capsule (used for treatment of rheumatism), Anfulong a-2b
Interferon (used for increasing immunity ), Ge Lie Qi Te (used for treatment of
diabetes), and Te Zi She Fu (used for diminishing inflammation).
The holding company and ultimate holding company is Tianjin Pharmaceutical
Hldgs, a company incorporated in Tianjin, China.
SGX source · Source update: 05/19/2026 08:45:31 AM (timezone not specified). Source text may be historical.